home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops
Search  -  prev / next
 
 

European Union Regulatory Issues - New Product Development

 
  January 24, 2018  
     
 
CfPIE - The Center for Professional Innovation & Education, Berlin, Germany
5 & 6 November, 2018


Course Description - Course runs 9:00 to 5:00 both days (Breakfast & Lunch Included)

This two-day course is designed to provide individuals with a detailed understanding of the important regulatory guidelines involved in the development of a new product plan within the EU. The program will also cover effective strategies for correctly applying the current regulations to ensure that rejections are avoided.

The course will provide the attendee with a thorough knowledge of the following topics:

  • How to develop a regulatory strategy
  • How to deal with pricing and reimbursement issues in your development
  • How to validate your regulatory strategy (scientific advice) and how to choose between centralized and national scientific advice
  • When does your product qualify as an orphan medicinal product and what are the advantages if it does?
  • How to deal with pediatric development plans
  • What has to be considered for Advanced Therapy Medicinal Product and oncology medicinal products

Who Should Attend

Attendance will be beneficial to personnel involved in new product development who need a thorough understanding of the issues affecting new medicinal products within the regulatory framework of the European Union.

The program will be useful to individuals who are seeking to update their knowledge of recent EMA regulatory changes and the impact these changes will have on the product development cycle.

 
 
Organized by: Center for Professional Innovation & Education
Invited Speakers:

Adriaan Fruijtier, M.Sc.

Specialties: Regulatory

Adriaan Fruijtier is currently Director Regulatory Affairs for CATS Consultants GmbH. Prior to joining CATS, he served as Head of the Oncology Group within the Global Regulatory Affairs division at Bayer AG in Wuppertal, Germany and the Bayer Corporation. He has also worked for the European Medicines Agency in London.

Previously, Mr. Fruijtier served as Director of Regulatory Affairs at Micromet AG and Regulatory Affairs Project Manager at Novartis AG in Basel, Switzerland. He also spent six years as Head of Drug Regulatory Affairs for Ciba-Geigy in the Netherlands.

Mr. Fruijtier received his M.Sc. in Pharmacy from the University of Utrecht, Netherlands.

Other Courses:

 
Deadline for Abstracts: N/A
 
Registration: https://www.cfpie.com/ProductDetails.aspx?ProductID=280
E-mail: info@cfpie.com
 
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2018 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.